Encyclopedia of Nanotechnology

Living Edition
| Editors: Bharat Bhushan

Interaction of the Immune System with Nanoparticles

  • Kirsten M. Pondman
  • Robert B. Sim
  • Uday Kishore
Living reference work entry
DOI: https://doi.org/10.1007/978-94-007-6178-0_100971-1

Synonyms

Definition

In most applications of nanomedicine, nanoparticles will come into contact with the skin, the gastrointestinal tract, the bloodstream, or other tissues in the body. Therefore, the nanoparticles will interact with the immune system. Interactions range from opsonization by immune or nonimmune proteins, uptake by phagocytic cells, and likely generation of antibodies. These immune processes can cause adverse inflammatory conditions and affect the intended target and delivery of the drugs by nanoparticles. Nanotherapeutics can also be strategically designed to interact with specific components of the immune system, either to stimulate or suppress the immune responses. These properties are useful for prophylactic vaccination and treatment of inflammatory and autoimmune diseases.

Introduction

Due to their advantageous physicochemical properties and increased targeting specificity, nanoparticle-based drugs can be effective at lower dose, with...

Keywords

Complement Activation Complement System Iron Oxide Nanoparticles NLRP3 Inflammasome Classical Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Thanou, M.: Nanoparticles for drug and gene delivery. In: Roberts, G.C.K. (ed.) Encyclopedia of Biophysics, pp. 1686–1691. Springer, Berlin (2013)Google Scholar
  2. 2.
    Dobrovolskaia, M.A., Aggarwal, P., Hall, J.B., McNeil, S.E.: Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487–495 (2008)CrossRefGoogle Scholar
  3. 3.
    Janeway, C.A., Travers, P., Walport, M., Shlomchik, M.J.: Immunobiology, 5th edn. Garland Science, New York (2001)Google Scholar
  4. 4.
    Lydyard, P.M., Whelan, A., Fanger, M.W.: Instant Notes Immunology. BIOS Scientific, Oxford (2000)Google Scholar
  5. 5.
    Abbas, A.K., Lichtman, A.H.: Cellular and Molecular Immunology. Saunders, Philadelphia (2009)Google Scholar
  6. 6.
    Kolev, M., Le Friec, G., Kemper, C.: Complement – tapping into new sites and effector systems. Nat. Rev. Immunol. 14, 811–820 (2014)CrossRefGoogle Scholar
  7. 7.
    Law, S.K.A., Reid, K.B.M.: Complement: In Focus. Oxford University Press (1995)Google Scholar
  8. 8.
    Carroll, M.C.: The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16, 545–568 (1998)CrossRefGoogle Scholar
  9. 9.
    Rybak-Smith, M., et al.: Recognition of Carbon Nanotubes by the Human Innate Immune System. In: Klingeler, R., Sim, R.B. (eds.) Carbon Nanotubes for Biomedical Applications, pp. 183–210. Springer, Heidelberg (2011)Google Scholar
  10. 10.
    Moghimi, S.M., et al.: Material properties in complement activation. Adv. Drug Deliv. Rev. 63, 1000–1007 (2011)CrossRefGoogle Scholar
  11. 11.
    Pondman, K.M.: Pristine and Modified Nanoparticles: Complement Activation and Immunomodulation. Enschede (2014)Google Scholar
  12. 12.
    Zhao, L., et al.: Nanoparticle vaccines. Vaccine 32, 327–337 (2014)CrossRefGoogle Scholar
  13. 13.
    Donaldson, K., et al.: Pulmonary toxicity of carbon nanotubes and asbestos – similarities and differences. Adv. Drug Deliv. Rev. (2013). doi:10.1016/j.addr.2013.07.014. [pii] S0169-409X(13)00168-3Google Scholar
  14. 14.
    Almeida, J.P.M., Figueroa, E.R., Drezek, R.A.: Gold nanoparticle mediated cancer immunotherapy. Nanomed. Nanotechnol. Biol. Med. 10, 503–514 (2014)CrossRefGoogle Scholar
  15. 15.
    Mitchell, L.A., Lauer, F.T., Burchiel, S.W., McDonald, J.D.: Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat. Nanotechnol. 4, 451–456 (2009)CrossRefGoogle Scholar
  16. 16.
    Ilinskaya, A.N., Dobrovolskaia, M.A.: Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br. J. Pharmacol. 171, 3988–4000 (2014)CrossRefGoogle Scholar
  17. 17.
    Zhou, J., Shum, K.T., Burnett, J.C., Rossi, J.J.: Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals 6, 85–107 (2013)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Kirsten M. Pondman
    • 1
    • 2
  • Robert B. Sim
    • 3
    • 4
  • Uday Kishore
    • 1
  1. 1.Centre for Infection, Immunity and Disease Mechanisms, College of Health and Life SciencesBrunel University LondonLondonUK
  2. 2.Neuro Imaging, MIRA InstituteUniversity of TwenteEnschedeThe Netherlands
  3. 3.Department of PharmacologyUniversity of OxfordOxfordUK
  4. 4.Department of Infection, Immunity and InflammationUniversity of LeicesterLeicesterUK